NCT01363466

Brief Summary

GYNECO 02 hypothesis is that hysterectomy reduces the possibility of local or loco-regional relapse, especially in patient with a reduced metastatic risk and who received a local chemoradiation therapy with an increase of radiotherapy doses (45 grays).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
61

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started May 2003

Typical duration for phase_3

Geographic Reach
1 country

35 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2003

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2006

Completed
4.5 years until next milestone

First Submitted

Initial submission to the registry

May 5, 2011

Completed
27 days until next milestone

First Posted

Study publicly available on registry

June 1, 2011

Completed
Last Updated

June 1, 2011

Status Verified

May 1, 2011

First QC Date

May 5, 2011

Last Update Submit

May 30, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Relapse free survival

    There is a follow-up period of 3 years.

    from randomization to relapse or last contact (up to 3 years)

Secondary Outcomes (1)

  • Overall Survival

    From randomisation to death or last contact (up to 3 years)

Study Arms (2)

with hysterectomy

EXPERIMENTAL
Procedure: hysterectomy

without hysterectomy

NO INTERVENTION

Interventions

hysterectomyPROCEDURE
with hysterectomy

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • operable Stage IB2/II Cervical Cancer
  • adenocarcinoma, squamous cell or adenosquamous carcinoma
  • Patient between 18 and 70 years old
  • No lombo-aortic lymph node invasion at baseline
  • Previous 45 grays external pelvic radiation with concomitant chemotherapy (cisplatin 40 mg/m2/week corresponding to 5 cycles)
  • Followed by a 15 grays utero-vaginal brachytherapy, eventually combined with a 6th cycle of chemotherapy (cisplatin 40 mg/m2)
  • with a pelvic boost if lymph node or parametrial invasion
  • No macroscopic residual tumor after 6 to 8 weeks after brachytherapy.

You may not qualify if:

  • Other tumor histology (neuro-endocrine)
  • Stage \> II (FIGO 1995) at baseline
  • Patient with remaining cervical cancer (after sub-total hysterectomy)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (35)

Clinique Axium

Aix-en-Provence, 13100, France

Location

Polyclinique du Parc Rambot

Aix-en-Provence, 13100, France

Location

Clinique Sainte Thérèse de l'enfant Jésus

Amiens, 80039, France

Location

Centre Hospitalier Universitaire

Amiens, 80054, France

Location

Centre Paul Papin

Angers, 49033, France

Location

Centre Hospitalier de Beauvais

Beauvais, 60021, France

Location

Institut Bergonié

Bordeaux, 33076, France

Location

Centre Hospitalier Nord Deux-Sèvres

Bressuire, 79302, France

Location

Centre Hospitalier Universitaire de Brest

Brest, 29609, France

Location

Centre Hospitalier Intercommunal

Créteil, 94010, France

Location

Centre Georges-François Leclerc

Dijon, 21034, France

Location

Centre Hospitalier de Fontainebleau

Fontainebleau, 77305, France

Location

Hôpital Hotel-Dieu

Lyon, 69288, France

Location

Centre Hospitalier Edouard Herriot

Lyon, 69437, France

Location

Centre Hospitalier Lyon Sud

Lyon, 69495, France

Location

Institut paoli Calmettes

Marseille, 13273, France

Location

Centre Hospitalier Régional Universitaire La Timone

Marseille, 13385, France

Location

Hôpital de la conception

Marseille, 13385, France

Location

Centre Hospitalier Régional Universitaire Hôpital Nord

Marseille, 13915, France

Location

Centre Hospitalier Universitaire - Hôpital Arnaud de Villeneuve

Montpellier, 34295, France

Location

Centre Val d'Aurelle-Paul Lamarque

Montpellier, 34298, France

Location

Centre hospitalier des Pays de Morlaix

Morlaix, 29205, France

Location

Centre René Gauducheau

Nantes, 44805, France

Location

Hôpital de la Source

Orléans, 45067, France

Location

Hôpital des Diaconnesses

Paris, 75571, France

Location

Hôpital Européen Georges Pompidou

Paris, 75908, France

Location

Centre Hospitalier Universitaire Jean Bernard

Poitiers, 86021, France

Location

Polyclinique de Courlancy

Reims, 51100, France

Location

Clinique Mutualiste de la Sagesse

Rennes, 35013, France

Location

Centre Universitaire Hospitalier- Hôpital Sud

Rennes, 35203, France

Location

Centre Henri Becquerel

Rouen, 76038, France

Location

Centre René Huguenin

Saint-Cloud, 92210, France

Location

Institut Claudius Régaud

Toulouse, 31052, France

Location

Centre Hospitalier Bretonneau

Tours, 37044, France

Location

Institut Gustave Roussy

Villejuif, 94805, France

Location

MeSH Terms

Conditions

Uterine Cervical NeoplasmsAdenocarcinomaCarcinoma, Squamous CellCarcinoma, Adenosquamous

Interventions

Hysterectomy

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasms, Squamous CellNeoplasms, Complex and Mixed

Intervention Hierarchy (Ancestors)

Gynecologic Surgical ProceduresUrogenital Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Philippe MORICE, Pr

    Gustave Roussy, Cancer Campus, Grand Paris

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 5, 2011

First Posted

June 1, 2011

Study Start

May 1, 2003

Study Completion

November 1, 2006

Last Updated

June 1, 2011

Record last verified: 2011-05

Locations